AstraZeneca’s 3-in-1 COPD inhaler Breztri gets FDA green light to play catch-up with GSK’s Trelegy
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does. The FDA has approved AstraZeneca’s three-in-one inhaler Breztri Aerosphere for the maintenance treatment of COPD, the company said Friday. The drug is… Read More »